HAE vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 19, 2026

HAE

35.3
AI Score
VS
BIO Wins

BIO

49.7
AI Score

Investment Advisor Scores

HAE

35score
Recommendation
SELL

BIO

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HAE BIO Winner
Revenue 339.38M 1.24B BIO
Net Income 33.01M -155.70M HAE
Gross Margin 59.8% 52.7% HAE
Net Margin 9.7% -12.5% HAE
Operating Income 57.46M 106.70M BIO
ROE 3.9% -2.2% HAE
ROA 1.4% -1.5% HAE
Total Assets 2.37B 10.25B BIO
Cash 223.38M 517.00M BIO
Debt/Equity 1.42 0.17 BIO
Current Ratio 3.08 3.14 BIO
Free Cash Flow 44.42M 144.80M BIO

Relative Price Performance (Last 90 Days)

HAE 1M: +9.5% · 3M: +52.1% BIO 1M: -6.3% · 3M: +16.9%

Current Technical Phase

HAE

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (12.8% over 20 days), RSI 67

RSI (14): 66.9 · Price: $118.73

BIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 39

RSI (14): 39.1 · Price: $352.82

Fundamentals Snapshot

Metric HAE BIO
Market Cap — —
Forward P/E 22.4 36.2
Trailing P/E 57.1 44.8
Revenue (TTM) — —
Revenue Growth 0.1% 0.0%
Gross Margin 0.6% 0.5%
Operating Margin 0.2% 0.1%
EPS 2.07 7.89
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.